Table 2 |
||||||
|
Cox regression analysis for breast cancer death for all patients (n = 179 to 200) |
||||||
| Univariate analysis |
Multivariate analysis |
|||||
|
|
|
|||||
| RR |
95 percent CI |
P |
RR |
95 percent CI |
P |
|
|
|
||||||
| Age, ≥55 years versus <55 years |
0.86 |
0.51–1.44 |
0.57 |
|||
| Tumor type (overall effect) |
0.14 |
|||||
| Lobular (versus ductal) |
0.56 |
0.30–1.06 |
0.074 |
|||
| Other (versus ductal) |
0.66 |
0.26–1.67 |
0.38 |
|||
| Tumor size (overall effect) |
0.001 |
0.002 |
||||
| pT2 (versus pT1) |
2.22 |
1.17–4.20 |
0.014 |
1.94 |
0.99–3.82 |
0.054 |
| pT3–pT4 (versus pT1) |
4.17 |
1.93–9.01 |
0.0003 |
4.44 |
1.95–10.1 |
0.0004 |
| Lymph node status (overall effect) |
0.035 |
0.027 |
||||
| pN1 (versus pN0) |
1.34 |
0.69–2.62 |
0.39 |
1.09 |
0.54–2.21 |
0.81 |
| pN2–pN3 (versus pN0) |
3.42 |
1.82–6.41 |
0.0001 |
2.73 |
1.41–5.30 |
0.003 |
| Othera (versus pN0) |
1.69 |
0.77–3.67 |
0.19 |
1.28 |
0.51–3.20 |
0.60 |
| Histological grade (overall effect) |
0.47 |
|||||
| G2 (versus G1) |
0.99 |
0.39–2.50 |
0.98 |
|||
| G3 (versus G1) |
1.43 |
0.52–3.90 |
0.49 |
|||
| TP53 mutation (versus wild type) |
4.51 |
2.69–7.56 |
<0.0001 |
5.24 |
3.03–9.07 |
<0.0001 |
| ER positive (versus negative) |
0.72 |
0.43–1.22 |
0.23 |
|||
| PR positive (versus negative) |
0.82 |
0.49–1.36 |
0.44 |
|||
|
|
||||||
|
aLymph nodes not removed. 95 percent CI, 95 percent confidence interval for relative risk; ER, estrogen receptor; PR, progesterone receptor;P, P value for the hypothesis of no effect; RR, relative risk (hazard ratio). |
||||||
|
Langerød et al. Breast Cancer Research 2007 9:R30 doi:10.1186/bcr1675 |
||||||
